NIH Guide: Weekly Index for March 13, 2020

Funding Opportunities

• Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
  (PA-20-135)
  National Institutes of Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of General Medical Sciences
  National Cancer Institute
  National Institute on Deafness and Other Communication Disorders
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Library of Medicine
  National Institute of Mental Health
  National Institute of Nursing Research
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Strategic Coordination (Common Fund)
  National Institute on Minority Health and Health Disparities
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): See the Emergency Notice of Special Interest (NOSI) for any applicable Application Due Dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
  (PAR-20-131)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 05, 2020
• Development and Maintenance of the Animal Feed Regulatory Program Standards with Optional Coordinated Preventive Control Regulatory Activities and Capacity Building (U18) Clinical Trial Not Allowed
  (PAR-20-132)
  Food and Drug Administration
  Application Receipt Date(s): May 13, 2020 by 11:59 PM Eastern Time. February 15, 2021 by 11:59 PM Eastern Time. February 15, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)
  (PAR-20-133)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Cancer Institute
  Application Receipt Date(s): June 18, 2020; June 8, 2021
• Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required)
  (PAR-20-134)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Cancer Institute
  Application Receipt Date(s): June 18, 2020; June 08, 2021
• Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)
  (PAR-20-136)
  National Cancer Institute
  Application Receipt Date(s): April 7, 2020; November 9, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022
• In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
  (PAR-20-137)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): June 5, 2020 (new) and July 5, 2020 (renewal, resubmission, revision); October 5, 2020 (new) and November 5, 2020 (renewal, resubmission, revision); June 5, 2021 (new) and July 5, 2021 (renewal, resubmission, revision); October 5, 2021 (new) and November 5, 2021 (renewal, resubmission, revision); June 5, 2022 (new) and July 5, 2022 (renewal, resubmission, revision); October 5, 2022 (new) and November 5, 2022 (renewal, resubmission, revision)
• Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
  (PAR-20-139)
  National Institute of Allergy and Infectious Diseases
  National Institute on Aging
  Application Receipt Date(s): May 13, 2020; September 13, 2020; January 13, 2021; May 13, 2021; September 13, 2021; January 13, 2022; May 13, 2022; September 13, 2022; January 13, 2023
• Artificial Intelligence and Technology Collaboratories for Aging Research (P30 Clinical Trial Optional)
  (RFA-AG-21-009)
  National Institute on Aging
  Application Receipt Date(s): October 1, 2020. No late applications will be accepted for this funding opportunity announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Artificial Intelligence and Technology Collaboratories for Aging Research Coordinating Center (AITCC) (R24 Clinical Trial Not Allowed)
  (RFA-AG-21-018)
  National Institute on Aging
  Application Receipt Date(s): October 1, 2020. No late applications will be accepted for this Funding Opportunity Announcement.
• Alzheimers Disease Research Centers (P30 Clinical Trial Not Allowed)
  (RFA-AG-21-019)
  National Institute on Aging
  Application Receipt Date(s): September 15, 2020 All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply corrections to errors found in the application during the submission process by the due date.
• Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61/R33 Clinical Trial Not Allowed)
  (RFA-AI-20-015)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
• Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
  (RFA-AI-20-028)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 29, 2020
• NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (BMOR) (P30 - Clinical Trials Not Allowed)
  (RFA-AR-21-004)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): August 11, 2020, by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization. All allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R01 Clinical Trial Not Allowed)
  (RFA-DE-20-006)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): July 8 20 , 2020 No late applications will be accepted for this Funding Opportunity Announcement
• Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R21 Clinical Trial Not Allowed)
  (RFA-DE-20-007)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): July 8, 2020; No late applications will be accepted for this Funding Opportunity Announcement
• Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)
  (RFA-DK-20-006)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): July 22, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
• Retail Food Safety Association Collaboration (U18) Clinical Trial Not Allowed
  (RFA-FD-20-028)
  Food and Drug Administration
  Application Receipt Date(s): May 13, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional
  (RFA-FD-20-030)
  Food and Drug Administration
  Application Receipt Date(s): May 11, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not Allowed
  (RFA-FD-20-031)
  Food and Drug Administration
  Application Receipt Date(s): May 18, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• Population Dynamics Centers Research Infrastructure Program FY 2021 (P2C Clinical Trial Not Allowed)
  (RFA-HD-21-010)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 30, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Postdoctoral Training in Pediatric Clinical Pharmacology (T32 Clinical Trial Not Allowed)
  (RFA-HD-21-014)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): May 27, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-HG-20-019)
  National Human Genome Research Institute
  Application Receipt Date(s): June 24, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (U24 Clinical Trial Optional)
  (RFA-HL-21-007)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): June 8, 2020
• Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional)
  (RFA-HL-21-008)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): June 8, 2020
• Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)
  (RFA-HL-21-009)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): June 8, 2020